The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Daniel Griffith Anderson net worth and biography

Daniel Anderson Biography and Net Worth

Director of Sigilon Therapeutics

Daniel G. Anderson, Ph.D., a co-founder of Sigilon Therapeutics, is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. Dr. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. Dr. Anderson’s work has resulted in the publication of over 400 papers, patents and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology and consumer product spaces including CRISPR Therapeutics AG, Living Proof, Inc., Verseau Therapeutics, Inc. and Olivo Laboratories, LLC.

What is Daniel Griffith Anderson's net worth?: The estimated net worth of Daniel Griffith Anderson is at least $3.50 million as of June 2nd, 2021. Dr. Anderson owns 155,555 shares of Sigilon Therapeutics stock worth more than $3,495,321 as of April 26th. This net worth approximation does not reflect any other assets that Dr. Anderson may own. Learn More about Daniel Griffith Anderson's net worth.
How old is Daniel Griffith Anderson?: Dr. Anderson is currently 53 years old. There are 5 older executives and no younger executives at Sigilon Therapeutics. The oldest executive at Sigilon Therapeutics is Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board, who is 74 years old. Learn More on Daniel Griffith Anderson's age.
How do I contact Daniel Griffith Anderson?: The corporate mailing address for Dr. Anderson and other Sigilon Therapeutics executives is , , . Sigilon Therapeutics can also be reached via phone at 617-336-7540 and via email at [email protected]. Learn More on Daniel Griffith Anderson's contact information.
Has Daniel Griffith Anderson been buying or selling shares of Sigilon Therapeutics?: Daniel Griffith Anderson has not been actively trading shares of Sigilon Therapeutics during the last quarter. Most recently, Daniel Griffith Anderson sold 15,384 shares of the business's stock in a transaction on Wednesday, June 2nd. The shares were sold at an average price of $130.00, for a transaction totalling $1,999,920.00. Following the completion of the sale, the director now directly owns 155,555 shares of the company's stock, valued at $20,222,150. Learn More on Daniel Griffith Anderson's trading history.
Are insiders buying or selling shares of Sigilon Therapeutics?: During the last year, Sigilon Therapeutics insiders bought shares 1 times. They purchased a total of 1,718,493 shares worth more than $25,639,915.56. The most recent insider tranaction occured on August, 11th when Major Shareholder Lilly & Co Eli bought 1,718,493 shares worth more than $25,639,915.56. Insiders at Sigilon Therapeutics own 6.5% of the company. Learn More about insider trades at Sigilon Therapeutics.
Information on this page was last updated on 8/11/2023.

Daniel Griffith Anderson Insider Trading History at Sigilon Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/2/2021	Sell	15,384	$130.00	$1,999,920.00	155,555

Daniel Griffith Anderson Buying and Selling Activity at Sigilon Therapeutics

Sigilon Therapeutics Company Overview

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $22.47

$22.09

$23.10

50 Day Range

MA: $22.02

$20.92

$23.06

2 Week Range

Now: $22.47

$3.77

$28.00

Volume

83,600 shs

Average Volume

62,902 shs

Market Capitalization

$56.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.12

Move Your Money Before May 22

From Stansberry Research | Ad